Nurix Therapeutics Inc 2025年季度报告

(Mark One) xQUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934For the quarterly period endedFebruary28, 2025ORoTRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934For the transition period fromtoCommission File Number:001-39398______________________________________________________________________ NURIX THERAPEUTICS, INC.(Exact Name of Registrant as Specified in its Charter) Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the SecuritiesExchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports),and (2) has been subject to such filing requirements for the past 90 days.YesxNoo Indicate by check mark whether the Registrant has submitted electronically every Interactive Data File required to be submittedpursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that theRegistrant was required to submit such files).YesxNoo Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reportingcompany, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reportingcompany,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. If an emerging growth company, indicate by check mark if the Registrant has elected not to use the extended transition period forcomplying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.o Indicate by check mark whether the Registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). YesoNox SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q contains forward-looking statements within the meaning of the Private SecuritiesLitigation Reform Act of 1995. All statements contained in this Quarterly Report on Form 10-Q other than statements of historicalfact, including statements concerning our business strategy and plans, future operating results and financial position, as well as ourobjectives and expectations for our future operations, are forward-looking statements. In some cases, you can identify forward-looking statements by such terminology as “believe,” “may,” “will,” “potentially,”“estimate,” “continue,” “anticipate,” “intend,” “could,” “would,” “project,” “plan,” “expect” and similar expressions that conveyuncertainty of future events or outcomes, although not all forward-looking statements contain these words. Forward-lookingstatements include, but are not limited to, statements about: •the timing and conduct of our clinical trial programs for our lead drug candidates bexobrutideg (NX-5948), NX-2127 andNX-1607 and other drug candidates, including statements regarding the timing of data and anticipated announcements,the selection of new development candidates and the initiation of clinical trials; •the timing of, and our ability to obtain, marketing approvals for our lead drug candidates bexobrutideg, NX-2127 andNX-1607 and other drug candidates;•our plans to pursue research and development of other drug candidates;•the timing of investigational new drug application (IND) submissions for our drug candidates;•the potential advantages of our DEL-AI platform, our drug candidates and degrader antibody conjugates (DACs);•the extent to which our scientific approach, our DEL-AI platform, protein degradation, antibody-drug conjugation, andDACs may potentially address a broad range of diseases;•the potential benefits of our arrangements with Gilead Sciences, Inc., Sanofi S.A. and Seagen Inc. (now a part of PfizerInc.);•the timing of and our ability to obtain and maintain regulatory approvals for our drug candidates;•the potential receipt of revenue from future sales of our drug candidates;•the rate and degree of market acceptance and clinical utility of our drug candidates;•our estimates regarding the potential market opportunity for our drug candidates;•our sales, marketing and distribution capabilities and strategy;•our ability to establish and maintain arrangements for the manufacturing of our drug candidates;•the expected impact of global business, political and macroeconomic conditions, including inflation, interest ratefluctuations and volatile market conditions, uncertainty with respect to the federal budget and debt ceiling, potentialgovernment shutdowns related thereto, cybersecurity events, instability in the global banking system, and global events,including regional conflicts around the world, on our business, clinical trials, financial condition, liquidity and results ofoperations;•the potential achievement of milestones and receipt of royalty payments under our collaborations;•our ability to enter into additional collaborations with third parties;